May 9-13: Who said What in Biotech and Pharmaceutical Industries?


These are the fresh promises that researchers and scientists made regarding their business and innovation and a hope that the collaborators filled us with to take R&D to a level higher and benefit the human race;

Quote 1.

Presently there are no effective treatments for hyperoxaluria in children. The granting of this designation highlights the increasing recognition that kidney stones and other complications of hyperoxaluria are a paediatric problem”-Who said it? Answer is here

Quote 2.

Takeda is honored to partner with the Gates Foundation to support the polio endgame. This represents a major commitment by a Japanese company to the health of children in developing countries around the world”-Who said it? Answer is here

Quote 3.

As a leader in hemophilia and evolving new treatment approaches for patients, Bayer has been an ideal partner for us to pursue our program in hemophilia A”-Who said it? Answer is here

Quote 4.

This shows that the antibody not only can exert pressure on the virus, but also can shorten the survival of infected cells. Our results explain why post-exposure prophylaxis–short-term treatment after exposure to HIV to reduce infection–with antibodies is more effective than ART in our mouse models”Who said it? Answer is here

Quote 5.

This ‘skin conforming’ platform brings with it transport properties that have significant promise to treat underlying conditions. For eczema or sun protection as examples, this second skin platform can then serve as a reservoir for controlled-release transdermal drug delivery or SPF ingredients, a possibility we are currently pursuing in our lab”-Who said it? Answer is here

Quote 6.

We want to find the best benefit to risk ratio, because we don’t want to make a treatment that is worse than the disease”-Who said it? Answer is here

Quote 7.

Our results represent the most complete characterization of adrenal cancer tissues, and many indicate a key to successful targeted therapy for this disease”Who said it? Answer is here

Quote 8.

From our observations, follistatin gene therapy is showing significant promise for patients with sIBM and other muscle-wasting disorders. We were gratified to discuss these encouraging findings with our colleagues at the ASGCT annual meeting, and we look forward to the day when this therapy becomes a standard treatment for patients affected by neuromuscular disease”-Who said it? Answer is here

Quote 9.

With the recent outbreak of viruses such as Zika and Ebola, achieving anti-viral breakthroughs becomes even more important. We are excited about the possibilities that this novel approach represents, and are looking to collaborate with universities and other organizations to identify new applications”-Who said it? Answer is here

Quote 10.

The continued strong commitment from our shareholders demonstrates the confidence they have in our team, our pipeline and the future of the Company. We remain committed to further developing novel medicines to provide improved treatment options for patients suffering from rare and devastating diseases such as HLH, autoimmune and inflammatory diseases or cancer”-Who said it? Answer is here

Quote 11.

With the approval of Empliciti in the EU, we are proud to extend our Immuno-Oncology science to multiple myeloma patients in Europe who have received at least one prior therapy”-Who said it? Answer is here


Leave a reply

Your email address will not be published. Required fields are marked *